Scancell Holdings PLC (LON:SCLP) technology is being used to develop a vaccine for the treatment of one of the most common and most aggressive forms of brain cancer.
Researchers at Nottingham Trent University and the University of Portsmouth have initiated a new preclinical study aimed at developing a vaccine for the treatment of glioblastoma multiforme, using Scancell’s Immunobody technology platform.
Glioblastoma multiforme accounts for just over half of all brain tumour diagnoses in the UK each year.
Current treatments are very limited and even with intensive chemotherapy; patients have an average survival time of just 14 months.
Using Scancell’s immunotherapy platform, scientists aim to develop a vaccine that stimulates the body’s immune system to target and kill the tumour cells.
“It is an aggressive disease and we believe the high avidity T cells generated by ImmunoBody will be needed to control its growth,” said chief scientific officer professor Lindy Durrant.